Company / Operating Cash Flow
Inhibrx Biosciences, Inc. Operating Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$129.8M
FY2025
5-year range
-$193.3M / -$129.8M
FY2023-FY2025
Trend
+32.9%
vs FY2024
Sector context
#138 of 216
Health Care
What the data says
At -$130M, Inhibrx Biosciences, Inc.'s operating cash flow ranks #138 of 216 in the Health Care sector. Improved from -$193M to -$130M over the past 2 years.
Based on SEC 10-K filings.
-$130M in FY2025.
Improved from -$193M to -$130M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#138 of 216 in Health CareTop 64% of 216This company -$129.8M Sector average $658.7M
▼
-119.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 32.9% year-over-year.
- Ranks #138 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$129.8M | +32.9% |
| FY2024 | -$193.3M | +0.0% |
| FY2023 | -$193.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026